NEW YORK, Nov. 17, 2014 /PRNewswire/ -- Kalorama Information believes that a new consortium will greatly enhance the use of miRNA (or microRNA). A data management organization, the RNAcentral Consortium, now offers the website RNAcentral (http://rnacentral.org) to serve as a unified resource for all types of noncoding RNA data. Kalorama says the consortium was developed by pooling information from a variety of sources, including databases and tools for browsing, contains approximately 8 million sequences and can assist companies entering the marketplace.
Kalorama's report, miRNA Research and Diagnostic Markets assesses the market opportunity for testing technologies that use these RNA types. The report can be found at http://www.kaloramainformation.com/redirect.asp?progid=86856&productid=8392022.
"By combining databases from different sources, it allows users the ability to explore different RNA sequences according to source, species, and molecular function." Said John Morrow, analyst for Kalorama Information. "This cannot help but accelerate developments. It is anticipated that further options will be made available in the future."
miRNAs (MicroRNAs) are short, single stranded RNAs that regulate mRNA expression at the post-transcriptional level. These small bits of RNA, members of a class of non-translated molecules that do not produce protein, shut off gene transcription by base pairing with the target molecules. They are now recognized as pivotal regulators of gene expression; including development, proliferation, differentiation, and apoptosis and serving widespread functions as regulatory molecules in post-transcriptional gene silencing. As the report details, a large number of companies, both small biotechs and big pharmaceutical companies are committed to miRNA diagnostics.
Kalorama says there is great interest currently in the use of miRNAs as biomarkers for cancer and other diseases, given their involvement in cancer initiation, progression, migration, invasion and metastasis. Large data bases offer the opportunity to search out and evaluate large numbers of sequences. The detection of these sequences in plasma of breast cancer patients may provide new biomarkers for a number of different cancers, with the potential to develop and introduce novel and non-invasive screening tests
Kalorama's report miRNA Research and Diagnostic Markets details over a dozen companies developing miRNA technologies. Companies are profiled and separate markets are broken out for the future of miRNA in research and the use of miRNA in diagnostics. Interviews with industry experts are provided. The report can be found at http://www.kaloramainformation.com/miRNA-Research-Diagnostics-8392022/
About Kalorama Information -- Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog.
SOURCE Kalorama Information